Enjoy complimentary customisation on priority with our Enterprise License!
The diabetic foot ulcers therapeutics market share is expected to increase by USD 1.74 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 7.01%.
This diabetic foot ulcers therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers diabetic foot ulcers therapeutics market segmentation by product (ischemic and neuro-ischemic ulcer therapeutics and neuropathic ulcer therapeutics) and geography (North America, Europe, Asia, and ROW). The diabetic foot ulcers therapeutics market report also offers information on several market vendors, including 3M Co., Baxter International Inc., ConvaTec Group Plc, Dr. Reddys Laboratories Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Merck and Co. Inc., Pfizer Inc., Smith and Nephew plc, and Viatris Inc. among others.
Download the Free Report Sample to Unlock the Diabetic Foot Ulcers Therapeutics Market Size for the Forecast Period and Other Important Statistics
Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The strong drug development pipeline is notably driving the diabetic foot ulcers therapeutics market growth, although factors such as the impact of complex pathogenesis in clinical trial design may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the diabetic foot ulcers therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Diabetic Foot Ulcers Therapeutics Market Driver
The strong drug development pipeline is one of the key drivers supporting the diabetic foot ulcers therapeutics market growth. The number of pipeline molecules for the treatment of diabetic foot ulcers is increasing at a significant pace. As of 2019, there were over ten different therapeutics undergoing various stages of clinical trials. The number of clinical trials is growing at a high rate. For instance, as of November 2020, Microbion Corp. is significantly focusing on the development of its potential candidate, MBN-101, which is currently in the pipeline. The drug has the potential to show dual broad-spectrum antimicrobial and anti-biofilm effects. Similarly, Oneness Biotech and ANTEROGEN are developing drugs for the treatment of diabetic foot ulcers. On obtaining regulatory approval, the molecules of these companies are likely to generate high revenue. Such developing factors will drive market growth during the forecast period.
Key Diabetic Foot Ulcers Therapeutics Market Trend
Increasing wound healing therapeutics is another factor supporting the diabetic foot ulcers therapeutics market growth. Wound healing occurs in four phases, including hemostasis, inflammatory, proliferative, and maturation. Various organizations are developing wound healing therapeutics for diabetic foot ulcers. For instance, ProNOx1 is in the Phase II stage of development by Edixomed for the treatment of diabetic foot ulcers. In addition, SER190 is under development by Serodus. It is in the preclinical stage of development for the treatment of diabetic foot ulcers. Wound healing therapeutics are likely to increase in number during the forecast period. This will contribute a major share of revenue to the global diabetic foot ulcers therapeutics market.
Key Diabetic Foot Ulcers Therapeutics Market Challenge
The impact of complex pathogenesis in clinical trial design is one of the factors hindering the diabetic foot ulcers therapeutics market growth. Diabetic foot ulcers are caused by numerous factors, such as peripheral neuropathy, structural foot deformity, and infection. Neuropathy and peripheral artery disease are associated with a high risk of developing foot ulcers. In addition, trauma is one of the main triggers. These complications can sometimes delay the healing process, which may ultimately lead to more complexities in treatment. The complexity of mechanisms involved in trials and related interventions determines the success of a trial. However, these interventions are mainly directed to certain defects in the foot care process. Failure of such trials and interventions due to their complexities will likely pose a challenge to the global diabetic foot ulcers therapeutics market during the forecast period.
This diabetic foot ulcers therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Technavio categorizes the diabetic foot ulcers therapeutics market as a part of the pharmaceutical market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the diabetic foot ulcers therapeutics market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the diabetic foot ulcers therapeutics market encompasses successful business strategies deployed by the key vendors. The diabetic foot ulcers therapeutics market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The diabetic foot ulcers therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the diabetic foot ulcers therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the pharmaceutical market includes the following core components:
The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.
***1. Executive Summary
***2. Market Landscape
**2.1 Market ecosystem
*Exhibit 01: Parent market
**2.2: Market Characteristics
**2.3 Value chain analysis
*Exhibit 02: Value chain analysis- Pharmaceuticals
*2.3.1 R&D and drug discovery
*2.3.2 Integration and product development
*2.3.3 Manufacturing
*2.3.4 Outbound logistics
*2.3.5 Marketing and sales
*2.3.6 Support services
*2.3.7 Innovation
***3. Market Sizing
**3.1 Market definition
*Exhibit 03: Offerings of vendors included in the market definition
**3.2 Market segment analysis
*Exhibit 04: Market segments
**3.3 Market size 2020
**3.4 Market outlook: Forecast for 2020 - 2025
*Exhibit 05: Global - Market size and forecast 2019 - 2024 ($ million)
*Exhibit 06: Global- Market size and forecast 2019-2024 ($ million), exclusive of COVID-19 impact
*Exhibit 07: Global market: Year-over-year growth 2019 - 2024 (%)
***4. Five Forces Analysis
**4.1 Five Forces Summary
*Exhibit 08: Five forces analysis 2020 & 2025
**4.2 Bargaining power of buyers
**4.3 Bargaining power of suppliers
**4.4 Threat of new entrants
**4.5 Threat of substitutes
**4.6 Threat of rivalry
**4.7 Market condition
*Exhibit 09: Market condition - Five forces 2019
***5. Market Segmentation by Product
**5.1 Market segments
*The segments covered in this chapter are:
*Exhibit 10: Product - Market share 2019-2024 (%)
**5.2 Comparison by Product
*Exhibit 11: Comparison by Product
**5.3 Ischemic and neuro-ischemic ulcer therapeutics - Market size and forecast 2019-2024
*Exhibit 12: Ischemic and neuro-ischemic ulcer therapeutics - Market size and forecast 2019-2024 ($ million)
*Exhibit 13: Ischemic and neuro-ischemic ulcer therapeutics - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact
*Exhibit 14: Ischemic and neuro-ischemic ulcer therapeutics - Year-over-year growth 2019-2024 (%)
**5.4 Neuropathic ulcer therapeutics - Market size and forecast 2019-2024
*Exhibit 15: Neuropathic ulcer therapeutics - Market size and forecast 2019-2024 ($ million)
*Exhibit 16: Neuropathic ulcer therapeutics - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact
*Exhibit 17: Neuropathic ulcer therapeutics - Year-over-year growth 2019-2024 (%)
**5.5 Market opportunity by Product
*Exhibit 18: Market opportunity by Product
***6. Customer landscape
**6.1 Customer landscape
*Exhibit 19: Customer landscape
***7. Geographic Landscape
**7.1 Geographic segmentation
*Exhibit 20: Market share by geography 2019-2024 (%)
**7.2 Geographic comparison
*Exhibit 21: Geographic comparison
**7.3 North America - Market size and forecast 2019-2024
*Exhibit 22: North America - Market size and forecast 2019-2024 ($ million)
*Exhibit 23: North America - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact
*Exhibit 24: North America - Year-over-year growth 2019-2024 (%)
**7.4 Europe - Market size and forecast 2019-2024
*Europe - Market size and forecast 2019-2024 ($ million)
*Exhibit 25: Europe - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact
*Exhibit 26: Europe - Year-over-year growth 2019-2024 (%)
**7.5 Asia - Market size and forecast 2019-2024
*Exhibit 27: Asia - Market size and forecast 2019-2024 ($ million)
*Exhibit 28: Asia - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact
*Exhibit 29: Asia - Year-over-year growth 2019-2024 (%)
**7.6 ROW - Market size and forecast 2019-2024
*Exhibit 30: ROW - Market size and forecast 2019-2024 ($ million)
*Exhibit 31: ROW - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact
*Exhibit 32: ROW - Year-over-year growth 2019-2024 (%)
**7.7 Key leading countries
*Exhibit 33: Key leading countries
**7.8 Market opportunity by geography
*Exhibit 34: Market opportunity by geography ($ million)
***8. Drivers, Challenges, and Trends
**8.1 Market drivers
*8.1.1 Strong drug development pipeline
*8.1.2 Increasing incidence of diabetic foot ulcers
*8.1.3 Rising number of diabetes awareness programs
**8.2 Market challenges
*8.2.1 Impact of complex pathogenesis in clinical trial design
*8.2.2 High entry barriers
*8.2.3 Poor wound care management
**8.3 Market trends
*8.3.1 Increasing wound healing therapeutics
*8.3.2 Increased outsourcing of non-core activities
*8.3.3 Increase in R&D activities
***9. Vendor Landscape
**9.1 Competitive scenario
**9.2 Vendor landscape
*Exhibit 35: Vendor Landscape
**9.3 Landscape disruption
*Exhibit 36: Landscape disruption
**9.4 Industry risks
*Exhibit 37: Industry risks
***10. Vendor Analysis
**10.1 Vendors covered
*Exhibit 38: Vendors covered
**10.2 Market positioning of vendors
*Exhibit 39: Market positioning of vendors
*10.3 3M Co.
*Exhibit 40: 3M Co. - Overview
*Exhibit 41: 3M Co. - Business segments
*Exhibit 42: 3M Co. - Key news
*Exhibit 43: 3M Co. - Key offerings
*Exhibit 44: 3M Co. - Segment focus
**10.4 Baxter International Inc.
*Exhibit 45: Baxter International Inc. - Overview
*Exhibit 46: Baxter International Inc. - Business segments
*Exhibit 47: Baxter International Inc. - Key news
*Exhibit 48: Baxter International Inc. - Key offerings
*Exhibit 49: Baxter International Inc. - Segment focus
**10.5 ConvaTec Inc.
*Exhibit 50: ConvaTec Inc. - Overview
*Exhibit 51: ConvaTec Inc. - Product and service
*Exhibit 52: ConvaTec Inc. - Key offerings
*10.6 Dr. Reddys Laboratories Ltd.
*Exhibit 53: Dr. Reddys Laboratories Ltd. - Overview
*Exhibit 54: Dr. Reddys Laboratories Ltd. - Business segments
*Exhibit 55: Dr. Reddys Laboratories Ltd. - Key news
*Exhibit 56: Dr. Reddys Laboratories Ltd. - Key offerings
*Exhibit 57: Dr. Reddys Laboratories Ltd. - Segment focus
**10.7 Fresenius SE & Co. KGaA
*Exhibit 58: Fresenius SE & Co. KGaA - Overview
*Exhibit 59: Fresenius SE & Co. KGaA - Business segments
*Exhibit 60: Fresenius SE & Co. KGaA - Key news
*Exhibit 61: Fresenius SE & Co. KGaA - Key offerings
*Exhibit 62: Fresenius SE & Co. KGaA - Segment focus
**10.8 GlaxoSmithKline Plc
*Exhibit 63: GlaxoSmithKline Plc - Overview
*Exhibit 64: GlaxoSmithKline Plc - Business segments
*Exhibit 65: GlaxoSmithKline Plc - Key news
*Exhibit 66: GlaxoSmithKline Plc - Key offerings
*Exhibit 67: GlaxoSmithKline Plc - Segment focus
**10.9 Merck & Co. Inc.
*Exhibit 68: Merck & Co. Inc. - Overview
*Exhibit 69: Merck & Co. Inc. - Business segments
*Exhibit 70: Merck & Co. Inc. - Key news
*Exhibit 71: Merck & Co. Inc. - Key offerings
*Exhibit 72: Merck & Co. Inc. - Segment focus
**10.10 Mylan NV
*Exhibit 73: Mylan NV - Overview
*Exhibit 74: Mylan NV - Business segments
*Exhibit 75: Mylan NV - Key news
*Exhibit 76: Mylan NV - Key offerings
*Exhibit 77: Mylan NV - Segment focus
**10.11 Pfizer Inc.
*Exhibit 78: Pfizer Inc. - Overview
*Exhibit 79: Pfizer Inc. - Business segments
*Exhibit 80: Pfizer Inc. - Key news
*Exhibit 81: Pfizer Inc. - Key offerings
*Exhibit 82: Pfizer Inc. - Segment focus
**10.12 Smith & Nephew Plc
*Exhibit 83: Smith & Nephew Plc - Overview
*Exhibit 84: Smith & Nephew Plc - Business segments
*Exhibit 85: Smith & Nephew Plc - Key news
*Exhibit 86: Smith & Nephew Plc - Key offerings
*Exhibit 87: Smith & Nephew Plc - Segment focus
***11. Appendix
**11.1 Scope of the report
*11.1.1 ????Market definition
*11.1.2 ????Objectives
*11.1.3 ????Notes and caveats
**11.2 Currency conversion rates for US$
*Exhibit 88: ?Currency conversion rates for US$?
**11.3 Research Methodology
*Exhibit 89: ?Research Methodology
*Exhibit 90: ??Validation techniques employed for market sizing?
*Exhibit 91: ??Information sources
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.